Ucb S.a. · EURONEXT:UCB
Ucb — H1 2023 Earnings Presentation
19 slides from Ucb's earnings presentation, Jul 27, 2023
Slide 1: HY 2023 Results
HY 2023 Results UCB Now at Inflection Point Our Purpose: Create value for patients, now and into the future Capital Market Earnings Call 27 July 2023
Slide 2: Disclaimer & Safe harbor
Disclaimer & Safe harbor This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking stat
Slide 3: Agenda
01 Jean-Christophe Tellier – CEO OVERVIEW UCB now at inflection point – ready to start a new phase of growth Proprietary and Confidential Property of UCB 02 Sandrine Dufour – CFO 2023 HY PERFORMANCE Financially healthy first 6 months 2023 – prepared for growth Guidance for 2023 confirmed Agenda 03 J
Slide 4: UCB now at inflection point – ready to start a new phase of growth
UCB now at inflection point – ready to start a Proprietary and Confidential Property of UCB new phase of growth Jean-Christophe Tellier CEO UCB - HY results 2023, July 2023 4
Slide 5: 2023 HY Performance | At-a-Glance
2023 HY Performance | At-a-Glance Reaching the inflection point & investing behind ongoing and upcoming launches – growth ahead € 2.6 bn Net sales: € 2.4 bn Revenue (-11%; -13% CER) (-12%; -14% CER) Underlying profitability € 801 M or 31% of revenue Proprietary and Confidential Property of UCB (adju
Slide 6: HY 2023 - approvals & launches and filings – more to come
HY 2023 - 4 approvals & launches and 3 filings – more to come Ongoing regulatory reviews = expected approvals, followed by launches Q1 2023 Q2 2023 Q3 2023 Q4 2023 H1 2024 H2 2024 CLINICAL 11 clinical study read-outs across UCB clinical pipeline in 2024 Proprietary and Confidential Property of UCB 2
Slide 7: Leading Epilepsy Portfolio Reached Inflection Point with Growth Drivers
Leading Epilepsy Portfolio Reached Inflection Point with 3 Growth Drivers 2023 HY Net Sales €M ACT CER € 2 378 M1 (-12%; -14% CER) Epilepsy € 957 M Generic erosion in Japan since January 2022 is (-33%; -32% CER) KEPPRA® € 336 -12% -9% now slowing down, important epilepsy drug in many regions for mil
Slide 8: UCB in generalized Myasthenia Gravis – Elevate Standard of Care
UCB in generalized Myasthenia Gravis – Elevate Standard of Care and Maximize Patient Outcomes gMG adult patient population** UCB gMG Portfolio – 2 different targeted therapies Anti-FcRn antibody ~120k Proprietary and Confidential Property of UCB 120k patients by 2032 First and only FDA approved FcRn
Slide 9: Commercial Execution in Immunology – Growth Drivers
Commercial Execution in Immunology – 3 Growth Drivers 2023 HY Net Sales € 2 378 M1 (-12%; -14% CER) €M ACT CER Immunology € 1 093 M Gaining market share in the anti-TNF (+8%; +8% CER) market based on differentiation CIMZIA® € 1 017 +2% +2% Patients are growing in all regions, Proprietary and Confide
Slide 10: Establishing Bone Builder Leadership with EVENITY
Establishing Bone Builder Leadership with EVENITY® Leading in U.S., Japan, South Korea, Australia, Canada, Belgium1 Worldwide Net Contribution from Amgen EVENITY® to UCB’s P&L Reach € 180 € 156 > 485 k Proprietary and Confidential Property of UCB € 140 € 132 patients at high risk of fracture reached
Slide 11: BIMZELX IL-17 Dynamic Leadership Leads to Sustained Patient Uptake
BIMZELX® IL-17 Dynamic Leadership Leads to Sustained Patient Uptake Estimated cumulative monthly treated patients IL-17 Dynamic Shares EU – JPN – CAN1 14 000 12 000 ≥35% Proprietary and Confidential Property of UCB 10 000 at the end of June 2023 8 000 6 000 Approved for PsA and axSpA in EU in JUN23
Slide 12: 2023 HY Performance
2023 HY Performance Financially healthy first 6 months 2023 – Proprietary and Confidential Property of UCB prepared for growth Guidance for 2023 confirmed Sandrine Dufour CFO UCB - HY results 2023, July 2023 12
Slide 13: HY 2023 | Reaching the Inflection Point
HY 2023 | Reaching the Inflection Point Ready for growth thanks to focused resource allocation and investments behind multiple launches Leaving loss of • Underlying net sales growth of plus exclusivity impacts 8% in the first six months behind us (adjusted for VIMPAT®) Proprietary and Confidential P
Slide 14: 2023 HY Financial Highlights
2023 HY Financial Highlights Inflection point towards growth and investment behind multiple launches HY 2023 Actual CER Net Sales € 2 378 M (-12%; -14% CER) Revenue Good portfolio growth compensated by LOE impacts VIMPAT® and E KEPPRA® € 2 589 M -11% -13% underlying net sales growth - adjusted for V
Slide 15: Financial Guidance for 2023 – Confirmed
Financial Guidance for 2023 – Confirmed Ready for growth, investing behind multiple launches, Zogenix acquisition becoming earnings accretive Revenue expected € 5.15 - 5.35 bn Peak sales guidance • Robust product portfolio • FINTEPLA® • Expected launches bimekizumab, Proprietary and Confidential Pro
Slide 16: We have strong growth ahead…
We have strong growth ahead… Proprietary and Confidential Property of UCB …creating value for all stakeholders, now and into the future Jean-Christophe Tellier CEO UCB - HY results 2023, July 2023 16
Slide 17: Inflection Point Reached
INFLECTION POINT CREATING Reached Value for all stakeholders, now and into the future BRINGING Proprietary and Confidential Property of UCB • New treatment options for people living with severe diseases • Growth and healthy profitability on a sustainable basis DELIVERING • Approvals and submissions
Slide 18: Thank you… your questions, please
Thank you… your questions, please 18 Proprietary and Confidential Property of UCB
Slide 19: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB